Hi I just looked at this over the i-net
VANCOUVER, June 2 /CNW-PRN/ - Biotech Holdings Ltd. is pleased to announce that its China subsidiary is expanding distribution of Biotech's newdiabetes drug, DIAB II, and is opening a sales office in Beijing.
In addition to marketing DIAB II in Hebei Province, a region of
approximately 60 million people near Beijing, Biotech has started distribution in Fujian Province in the south and the cities of Dalian in the north, Xian in the northwest and Shenzhen in the south. Biotech will also be opening a sales office in Beijing, the national capital. Together, these regions include a population of over 100 million people, with over 10 million diabetics who are potential patients for DIAB II. There are over 60 million people suffering from Type II Diabetes in China, making this one of the most important markets
in the world for the drug.
The first market to be addressed outside China is the Caribbean, where, according to World Health Organization statistics, Type II Diabetes affects over 15% of the population and is the number two cause of death and disability behind only heart disease. Biotech has clinical trials under way in this region.
The Company is currently in discussions with multi-national drug
companies interested in licensing DIAB II for sales in North America and Western Europe.
Biotech Holdings' is a company located in Vancouver, Canada with its plant in Richmond B.C. Biotech's primary focus is the manufacture and international marketing of DIAB II, a new prescription drug, taken in tablet form, for the treatment of Type II Diabetes. Type II Diabetes afflicts over 200 million people worldwide, and is one of the leading causes of human suffering and death.
SOURCE Biotech Holdings Ltd.
CONTACT: Biotech Holdings Ltd. at (888) 216-1111
Is there any place that you can verify the results Biotech claims in a technical bulletin? Jacques |
